<DOC>
	<DOCNO>NCT01269437</DOCNO>
	<brief_summary>This open-label , randomize , parallel Group , multicenter study evaluate efficacy safety budesonide novolizer dry powder inhaler compare budesonide turbuhaler dry powder inhaler Chinese mild moderate asthma patient .</brief_summary>
	<brief_title>Efficacy Safety Study Budesonide Novolizer Dry Powder Inhaler 200μg Treat Chinese Patients With Mild Moderate Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Provision inform consent subject his/her legal guardian subject 18 year old . Male female age 12 70 Had definite diagnosis asthma symptom cough/expectoration/chest tightness/wheeze/breathlessness within last one month Inhaled corticosteroid ( ICS ) naïve regular use ICS within last one month ( It suggest ICS average daily dose 100mg budesonide equal within last month `` Noregularuse '' ) FEV1 60 % 85 % predict normal value Reversibility test airway obstruction positive , i.e . degree reversibility FEV1 12 % ( include ) 200ml ( include ) . Or average diurnal PEFR variability le 20 % two week . Are able use Peak Flow Meter record patient diary card Asthma exacerbation lead hospitalization 2 day within last 6 month emergency room visit due asthma exacerbation last 3 month prior screen Infection respiratory system last 4 week prior screen visit Use oral , injectable , rectal transdermal glucocorticoid last 4 week prior screen visit Use Leukotriene receptor antagonist ( LTRAs ) , oral b2 agonist , methylxanthines use inhale long act b2 agonist , inhale anticholinergic receptor last 1 week , inhale Tiotropium Bromide within 45 day prior screen visit Patients chronic obstructive pulmonary disease ( COPD ) COPD asthma Patients severe persistent asthma ( Based definition GINA 2006 ) Patients specific immunity treatment ( include monoclonal antibody treatment ) due asthma within 6 month prior screen visit Patients eye disorder include cataract , glaucoma herpes virus infection Smoking history 10 packyear ( 1 packyear refers 20 cigarette per day 1 year ) History drug alcohol abuse History adrenal disease History malignancy disease last 5 year , exception basal cell carcinoma Heart function failure severe systematic disease , investigator 's discretion , make undesirable patient participate trial could jeopardize compliance trial protocol ALT AST &gt; 2 time upper limit reference range Creatinine ( Cr ) &gt; 159µmol/L male &gt; 141µmol/L female Patients hypersensitivity budesonide and/or lactose Participation clinical study treatment nonapproved experimental medication last 1 month Pregnant breastfeeding woman , woman childbearing age without appropriate contraception measure Limitations : The following medication prohibit screen onward : Use oral , injectable , rectal transdermal glucocorticoid Inhaled nedocromil sodium/Inhaled cromoglycate sodium Leukotriene receptor antagonist Methylxanthines Inhaled long act b2 agonist Oral b2 agonist Inhaled anticholinergic receptor Any b2 receptor blocker ( Including eye drop )</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>mild moderate asthma</keyword>
</DOC>